Form 4: Gilde Healthcare Trims LAVA Therapeutics Stake

Cooperatieve Gilde Healthcare IV U.A., a 10% owner and director of LAVA Therapeutics NV, reported the sale of 475,027 common shares over three days in October 2025.

Summary

• Cooperatieve Gilde Healthcare IV U.A., identified as a 10% owner and director of LAVA Therapeutics NV (LVTX), reported multiple sales of common shares.
• On October 13, 2025, 47,686 common shares were sold at a weighted average price of $1.54 per share.
• On October 14, 2025, 227,341 common shares were sold at a weighted average price of $1.51 per share.
• On October 15, 2025, 200,000 common shares were sold at a weighted average price of $1.51 per share.
• The total number of common shares sold across these three transactions amounts to 475,027.
• Following these reported transactions, Cooperatieve Gilde Healthcare IV U.A. directly holds 4,819,151 common shares.
• Gilde Healthcare IV Management BV and Gilde Healthcare Holding B.V. disclaim beneficial ownership of the shares held by Gilde Healthcare, except to the extent of their respective pecuniary interests therein.

Sentiment

Score: 3

Explanation: The sale of a substantial number of shares by a 10% owner and director is typically viewed negatively by the market, suggesting a potential lack of confidence or a strategic divestment. This could exert downward pressure on the stock price.

Negatives

• A significant 10% owner and director, Cooperatieve Gilde Healthcare IV U.A., has reduced its stake in LAVA Therapeutics NV by selling 475,027 common shares.
• The sales occurred at weighted average prices ranging from $1.51 to $1.54 per share, indicating a decision to divest at current market levels.
• The reduction in ownership by a major institutional investor and board member could signal a lack of confidence in the company's near-term prospects or a strategic reallocation of capital away from LVTX.

Risks

• Increased selling pressure on LAVA Therapeutics NV's stock due to the significant volume of shares sold by a major holder.
• Potential negative investor sentiment as a key insider and 10% owner reduces their stake, which could be interpreted as a bearish signal.
• Risk of further insider selling if this divestment is part of a larger strategic exit or reduction in exposure.

Future Outlook

The Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.
• Gilde Healthcare IV Management BV and Gilde Healthcare Holding B.V. disclaim beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information to analyze broader industry trends or competitor activities. It solely focuses on the change in beneficial ownership by a specific institutional investor in LAVA Therapeutics NV.

Related Party Transactions

• The reported transactions involve Cooperatieve Gilde Healthcare IV U.A., which is identified as a 10% owner and director of LAVA Therapeutics NV, making these related-party transactions.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Company management could face questions regarding the reasons for the major shareholder's divestment and its implications for future strategic direction.

Key Dates

Recommendation

The sale of a substantial block of shares by a 10% owner and director, Cooperatieve Gilde Healthcare IV U.A., is a strong negative signal. Such insider selling often indicates that a well-informed party believes the stock is fully valued or that future prospects are dim. This action could lead to decreased investor confidence and further downward pressure on LAVA Therapeutics NV's share price, warranting a 'sell' recommendation for investors.

Keywords

LAVA Therapeutics, LVTX, Gilde Healthcare, insider selling, Form 4, beneficial ownership, share divestment, institutional investor, director transaction